Path Fertility works with doctors and fertility specialists to provide couples who are trying to conceive with answers. Using breakthrough technology, Path Fertility has developed a sperm analysis test that is more predictive of pregnancy than the current standard of care semen analysis alone. SpermQT examines epigenetic biomarkers and DNA methylation within the sperm head--looking beyond typical criteria of male fertility such as sperm count, motility, and concentration. Despite common misconceptions, fertility problems are common (1 in 6 people) and impact both men and women equally. The gender divide in both fertility testing and treatment has left not only a gap in potential interventions, but also in the emotional burden that partners experience. Path Fertility is on a mission to raise the standard of care for male reproductive health. Male fertility is a women's health issue. When subfertile men go undiagnosed, women are put through fertility treatments that will not work. Powered by Inherent Biosciences.